<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6765">
  <stage>Registered</stage>
  <submitdate>6/08/2017</submitdate>
  <approvaldate>6/08/2017</approvaldate>
  <nctid>NCT03314298</nctid>
  <trial_identification>
    <studytitle>A Single Dose Trial to Evaluate the Pharmacokinetics of Testosterone and Anastrozole</studytitle>
    <scientifictitle>A Single Dose Trial to Evaluate the Pharmacokinetics of Testosterone and Anastrozole From Subcutaneous Testosterone and Anastrozole (T+Ai) in Premenopausal Women</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>HAV-001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Mammographic Density</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - testosterone anastrozole

Experimental: testosterone anastrozole implant - testosterone 80mg Anastrozole 4 mg single as a subcutaneous pellet


Treatment: drugs: testosterone anastrozole
subcutaneous testosterone and anastrozole

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>testosterone Cmax - Peak Plasma Concentration</outcome>
      <timepoint>Day 1, blood samples will be taken pre-dose and at 1, 2, 4, 8 and 12 hours and 9 am in the morning on Days 2, 3, 4, 5, 8, 15, 22, 29, 43, 57, 71 and 85.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>testosterone AUC - Area under the plasma concentration versus time curve</outcome>
      <timepoint>Day 1, blood samples will be taken pre-dose and at 1, 2, 4, 8 and 12 hours and 9 am in the morning on Days 2, 3, 4, 5, 8, 15, 22, 29, 43, 57, 71 and 85.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>testosterone T1/2 - plasma half-life</outcome>
      <timepoint>Day 1, blood samples will be taken pre-dose and at 1, 2, 4, 8 and 12 hours and 9 am in the morning on Days 2, 3, 4, 5, 8, 15, 22, 29, 43, 57, 71 and 85.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>anastrozole Cmax - Peak Plasma Concentration</outcome>
      <timepoint>Day 1, blood samples will be taken pre-dose and at 1, 2, 4, 8 and 12 hours and 9 am in the morning on Days 2, 3, 4, 5, 8, 15, 22, 29, 43, 57, 71 and 85.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>anastrozole AUC - Area under the plasma concentration versus time curve</outcome>
      <timepoint>Day 1, blood samples will be taken pre-dose and at 1, 2, 4, 8 and 12 hours and 9 am in the morning on Days 2, 3, 4, 5, 8, 15, 22, 29, 43, 57, 71 and 85.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>anastrozole T1/2 - plasma half-life</outcome>
      <timepoint>Day 1, blood samples will be taken pre-dose and at 1, 2, 4, 8 and 12 hours and 9 am in the morning on Days 2, 3, 4, 5, 8, 15, 22, 29, 43, 57, 71 and 85.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] - To assess the safety and tolerability of T+Ai following a single dose of T+Ai by subcutaneous implantation.
Biochemical and hematological will be evaluated and the number of participants with abnormal values or adverse events that are related to treatment will be recorded</outcome>
      <timepoint>The outcome measures will be reported weekly until study completion-3 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>dihydrotestosterone metabolism - To description of the time course of dihydrotestosterone serum concentrations.</outcome>
      <timepoint>3 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>breast elasticity - Breast tissue elasticity will be measured by shear wave ultrasound at baseline and on Days 29, 57 and 85. A Supersonic Ultrasound will be carried out by four quadrant analysis of each breast with 6x3mm Q box analyses measured in kPa.</outcome>
      <timepoint>Breast tissue elasticity will be measured by shear wave ultrasound at baseline and on Days 29, 57 and 85</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Agree to and be capable of understanding and signing an Informed Consent Form.

          2. Patients seeking treatment with Investigational Product for the reduction in high
             mammographic breast density (MBD).

          3. Pre-menopausal levels of Follicular stimulating hormone/Leutinizing
             hormone/estradiol(follicle stimulating hormone/luteinizing hormone/oestrogen)
             according to the definition of "pre-menopausal range" for the laboratory involved.

          4. Volpara Density volumetric breast density of =15.5% (combined average both breasts)

          5. Age between 35-55 years inclusive.

          6. Body weight between 50-90 kg inclusive.

          7. BMI between 20-30 kg/m2 inclusive.

          8. Good venous access for venepuncture.

          9. In good general health without clinically significant cardiac, respiratory, or
             psychiatric disease.

         10. Negative pregnancy test in women of childbearing potential (premenopausal or less than
             12 months of amenorrhea post-menopause, and who have not undergone surgical
             sterilisation), no more than seven days before the first dose of Investigational
             Product.

         11. For women of childbearing potential who are sexually active, agreement to use a highly
             effective, non-hormonal form of contraception (Mirena (TM) allowed) during and for at
             least six months after completion of treatment with Investigational Product; OR, a
             fertile male partner willing and able to use effective non-hormonal means of
             contraception (barrier method of contraception in conjunction with spermicidal jelly,
             or surgical sterilisation) during and for at least six months after completed dosing
             Investigational Product.</inclusivecriteria>
    <inclusiveminage>35</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>55</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Female</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>1. Presence of breast cancer.

          2. Previous or concomitant other malignancy (non-breast, other than skin) within the
             previous five years.

          3. Diabetes mellitus or glucose intolerance defined as a fasting glucose of = 6 mmol/L.

          4. History of coronary artery disease.

          5. Risk of transmitting Human Immunodeficiency Virus or viral hepatitis via infected
             blood.

          6. Existing testosterone, oestrogen and/or anastrozole treatment.

          7. Concomitant medication which induces or inhibits CYP3A4 (Listed in Appendix A).

          8. Current warfarin usage.

          9. Prolonged systemic corticosteroid treatment, inhalation and topical steroids allowed.

         10. Known hypersensitivity to any component of Investigational Product.

         11. Systemic reproductive hormone replacement therapy.

         12. Systemic hormonal contraception.

         13. Participation in another clinical trial of an Investigational Product within 30 days
             of entry into the present trial or within 4-5 half-lives of the Investigational
             Product, whichever is the longer.

         14. Use of any product containing ginseng within 30 days of screening.

         15. Pregnant or lactating women.

         16. Unable to comply with trial requirements.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>14/08/2017</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>12</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>14/02/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA</recruitmentstate>
    <hospital>Wellend Health - Toorak Gardens</hospital>
    <postcode>5065 - Toorak Gardens</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Havah Therapeutics Pty Ltd</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>A single dose trial to evaluate the pharmacokinetics of testosterone and anastrozole from
      subcutaneous testosterone and anastrozole (T+Ai) in premenopausal women</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT03314298</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Stephen N Birrell, Md PhD</name>
      <address>Wellend Health</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Stephen N Birrell, MD PhD</name>
      <address />
      <phone>+61419804741</phone>
      <fax />
      <email>steve@wellendhealth.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>